HC Wainwright Comments on Biomea Fusion Q1 Earnings

Key Points

• HC Wainwright forecasts Biomea will report a Q1 2026 loss of ($0.12) per share and projects FY2026 EPS of ($0.57) with losses widening to ($0.78) by FY2028; the article cites a consensus full-year estimate of ($3.93) per share.
• Analyst coverage is mixed but leans positive, with an average rating of Moderate Buy, a consensus price target of $8.63, and an analyst breakdown of 1 Strong Buy, 7 Buy, 1 Hold and 1 Sell.
• Shares jumped about 12.3% to $1.37 (market cap ~$99M) and institutional investors own roughly 96.7% of the stock; Biomea’s lead clinical asset is BMF-219, an oral menin–MLL inhibitor targeting epigenetic drivers of cancer.

Biomea Fusion, Inc. (NASDAQ:BMEA - Free Report) - Equities researchers at HC Wainwright issued their Q1 2026 earnings estimates for Biomea Fusion in a research report issued to clients and investors on Wednesday, March 25th. HC Wainwright analyst J. Pantginis forecasts that the company will post earnings of ($0.12) per share for the quarter. The consensus estimate for Biomea Fusion's current full-year earnings is ($3.93) per share. HC Wainwright also issued estimates for Biomea Fusion's Q2 2026 earnings at ($0.14) EPS, Q3 2026 earnings at ($0.15) EPS, Q4 2026 earnings at ($0.15) EPS, FY2026 earnings at ($0.57) EPS, FY2027 earnings at ($0.64) EPS and FY2028 earnings at ($0.78) EPS.

Other equities research analysts have also issued reports about the stock. Rodman & Renshaw began coverage on shares of Biomea Fusion in a research note on Tuesday, January 13th. They set a "buy" rating and a $8.00 target price for the company. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Biomea Fusion in a report on Wednesday, January 21st. Finally, D. Boral Capital reiterated a "buy" rating and set a $12.00 price objective on shares of Biomea Fusion in a research report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $8.63.

Biomea Fusion Trading Up 12.3%

Shares of BMEA stock opened at $1.37 on Friday. Biomea Fusion has a 12-month low of $0.87 and a 12-month high of $3.08. The stock has a market capitalization of $99.05 million, a P/E ratio of -1.05 and a beta of -0.20. The firm's 50 day moving average is $1.29 and its 200 day moving average is $1.43.

Institutional Trading of Biomea Fusion

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Aisling Capital Management LP boosted its stake in shares of Biomea Fusion by 156.5% during the 2nd quarter. Aisling Capital Management LP now owns 2,048,757 shares of the company's stock worth $3,688,000 after acquiring an additional 1,250,000 shares during the last quarter. XTX Topco Ltd grew its position in shares of Biomea Fusion by 77.1% during the 3rd quarter. XTX Topco Ltd now owns 265,303 shares of the company's stock valued at $536,000 after acquiring an additional 115,524 shares during the period. State Street Corp increased its stake in shares of Biomea Fusion by 17.8% in the 4th quarter. State Street Corp now owns 165,115 shares of the company's stock worth $205,000 after purchasing an additional 25,000 shares in the last quarter. Jain Global LLC purchased a new stake in shares of Biomea Fusion in the 4th quarter worth $68,000. Finally, ADAR1 Capital Management LLC bought a new position in Biomea Fusion in the 4th quarter worth $54,000. 96.72% of the stock is owned by hedge funds and other institutional investors.

Biomea Fusion Company Profile

Biomea Fusion, Inc NASDAQ: BMEA is a clinical‐stage biopharmaceutical company headquartered in Carlsbad, California. The company is dedicated to the discovery and development of small molecule therapies that target epigenetic regulators implicated in cancer. By leveraging a proprietary chemistry and drug discovery platform, Biomea Fusion aims to design precision medicines that modulate gene expression pathways involved in the initiation and progression of hematological malignancies and solid tumors.

The company's lead clinical asset, BMF-219, is an orally bioavailable inhibitor of the menin–mixed‐lineage leukemia (MLL) protein–protein interaction.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.